CPH to list on the OTC as it expands North American footprint
Creso Pharma (ASX:CPH) today announced it is listing on the OTC market in the USA.
CPH is on trend with several ASX stocks that have listed on the OTC (Over the Counter) exchange in the US including:
- Novonix was as high as 152% and is currently up 79%
- Tinybeans is up 36.9% since its OTC announcement
- FYI Resources Ltd has only been trading on the OTC for a month and is up 48%
- European Metals Holdings Ltd is up 85% in the three months since its OTC listing
Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.
Creso Pharma expects that the OTC listing will provide greater access to the North American capital markets and easier comparisons to US and Canadian listed peers.
CPH also feels its dual listing will bridge its valuation gap against its competitors: a number of competitors are currently trading at valuations between US$500M up to US$15BN on international exchanges, and many are less advanced.
The listing is expected to take approximately 45 days and once complete will form part of CPH’s strategy to raise global awareness of its operations in the cannabis and psychedelics medicines space.
“The Company is very excited about its proposed OTC dual listing,” Non-executive Chairman Adam Blumenthal said. “Creso Pharma has a growing global footprint and the OTC will provide a platform for the Company to boost its visibility to a broad base of US investors, particularly as cannabis moves towards legalisation. We look forward to updating shareholders on the listing process in the coming weeks.”
Halucenex to play a key role in CPH’s global recognition
News of the OTC listing coincides with CPH acquisition target Halucenex Life Sciences securing an additional supply of 700 mg of pharmaceutical grade psilocybin, otherwise known as magic mushrooms, for use in its upcoming clinical trial program, adding to the 11.6g previously secured.
Halucenex is an established psychedelics company focused on developing psychedelic-based treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.
There are a number of US and Canadian cannabis and psychedelic medicine stocks that point the way for the $200M capped CPH:
- Mindmed is capped at $1.18BN
- Compass Pathways plc is capped at $1.41BN
Currently capped at ~ $200M, CPH wants to see if its valuation can catch up to its billion dollar plus North American peers.
Importantly, Halucenex is only one of 11 companies to secure psilocybin supply in Canada, with its relationship with manufacturing partners significantly de-risking clinical trial timelines.
The additional supply of psilocybin provided is GMP certified, which means it does not have be certified with regulators.
Further, the bolstered inventory allows ample runway for Halucenex to progress research initiatives including Phase II and Phase III clinical trials and stable pricing metrics.
There is currently a growing interest in psychedelic inspired medicines and a bottleneck in the supply chain for synthetic psilocybin as more companies enter the research domain.
This means awareness should grow quickly.
“Securing an additional supply of psilocybin is a very pleasing development and highlights the strength of Halucenex’s relationship with Canada’s only manufacturer,” Blumenthal said.
“We are very excited to progress the upcoming clinical trial program and are confident that the initiative will add to the growing body of evidence for the use of psychedelic medicines as a much needed alternative.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.